4135-11-9
Chemical Structure
Polymyxin B1
- CAS No.: 4135-11-9
- Formula:C56H98N16O13
- Molecular Weight:1203.48
IUPAC Name: (S)-N-((S)-4-amino-1-(((2S,3R)-1-(((S)-4-amino-1-oxo-1-(((3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-((R)-1-hydroxyethyl)-12-isobutyl-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl)amino)butan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)amino)-1-oxobutan-2-yl)-6-methyloctanamide
InChIKey: WQVJHHACXVLGBL-CTMZAJDNSA-N
SMILES: O=C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@@]1([H])[C@H](O)C)=O)CCN)=O)([H])CCN)=O)CC(C)C)[C@H](NC([C@@H](NC([C@@](CCNC1=O)([H])NC([C@H](CCN)NC([C@H]([C@H](O)C)NC([C@H](CCN)NC(CCCC[C@@H](C)CC)=O)=O)=O)=O)=O)CCN)=O)CC2=CC=CC=C2
Biological Activity: Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Polymyxin B1 | 98.90% | Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Polymyxin B1-d7 TFA | 98.18% | Polymyxin B1-d7 TFA is the deuterium labeled Polymyxin B1 TFA (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kwa AL, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb;60(2):163-7. [Content Brief]
- [2]. Berglund NA, et al. Interaction of the antimicrobial peptide polymyxin B1 with both membranes of E. coli: a molecular dynamics study. PLoS Comput Biol. 2015 Apr 17;11(4):e1004180. [Content Brief]
